 TG Therapeutics Inc NASDAQ: TGTX shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee ODAC meeting for marketing application regarding ublituximab Ukoniq umbralisib U2 combo. U2 Combo application seeks approval for chronic lymphocytic leukemia CLL and small lymphocytic lymphoma SLL. 